ZNF677 Downregulation in Non-Small Cell Lung Cancers

Researchers at the Medical University of Vienna discovered that ZNF677 is downregulated in non-small cell lung cancers (NSCLC) due to tumor-specific methylation. This study investigated the role of ZNF677 in NSCLC by comparing its expression in primary tumor and non-malignant lung tissue samples from 1,000 patients. The results showed that ZNF677 expression is downregulated in tumors compared to non-malignant tissue, with a statistically significant difference (adjusted p-values < 0.05).

Key Takeaways:

• ZNF677 is downregulated in non-small cell lung cancers (NSCLC) due to tumor-specific methylation.
• Methylation is the main mechanism for ZNF677 downregulation in NSCLC cells.
• ZNF677 methylation is tumor-specific in NSCLC patients, with a statistically significant difference (p < 0.05).
• The study suggests that ZNF677 has tumor cell growth suppressing properties in NSCLCs.
• ZNF677 methylation may serve as a prognostic parameter in NSCLC patients.
• The research was conducted on a large cohort of 1,000 NSCLC patients.
• Investigators at the Medical University of Vienna, led by G. Heller, were responsible for the study.

Statistics:

• 1,000 NSCLC patients were included in the study.
• ZNF677 expression was compared in primary tumor and non-malignant lung tissue samples from 1,000 patients.
• Adjusted p-values < 0.05 indicated statistically significant differences in ZNF677 expression between tumors and non-malignant tissue.
• The study observed tumor-specific ZNF677 methylation in NSCLC patients, with a statistically significant difference (p < 0.05).

Sources:

• "DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers." Oncotarget, 2015;6(1):394-408
• Medical University of Vienna, Clinical Division of Oncology, Department of Medicine I
• Medical University of Vienna, Comprehensive Cancer Center